CZ20013988A3 - Enantiomerem obohacené 1,5-benzodiazepinové deriváty - Google Patents

Enantiomerem obohacené 1,5-benzodiazepinové deriváty Download PDF

Info

Publication number
CZ20013988A3
CZ20013988A3 CZ20013988A CZ20013988A CZ20013988A3 CZ 20013988 A3 CZ20013988 A3 CZ 20013988A3 CZ 20013988 A CZ20013988 A CZ 20013988A CZ 20013988 A CZ20013988 A CZ 20013988A CZ 20013988 A3 CZ20013988 A3 CZ 20013988A3
Authority
CZ
Czechia
Prior art keywords
enantiomer
formula
cck
compound
receptors
Prior art date
Application number
CZ20013988A
Other languages
Czech (cs)
English (en)
Inventor
David Colclough
Anne Hodgson
Jerzy Ryszard Szewczyk
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9910366.5A external-priority patent/GB9910366D0/en
Priority claimed from GBGB0008179.4A external-priority patent/GB0008179D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of CZ20013988A3 publication Critical patent/CZ20013988A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CZ20013988A 1999-05-06 2000-05-04 Enantiomerem obohacené 1,5-benzodiazepinové deriváty CZ20013988A3 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9910366.5A GB9910366D0 (en) 1999-05-06 1999-05-06 1,5-Benzodiazepine Derivatives
GBGB0008179.4A GB0008179D0 (en) 2000-04-05 2000-04-05 Chemical process

Publications (1)

Publication Number Publication Date
CZ20013988A3 true CZ20013988A3 (cs) 2002-02-13

Family

ID=26244033

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20013988A CZ20013988A3 (cs) 1999-05-06 2000-05-04 Enantiomerem obohacené 1,5-benzodiazepinové deriváty

Country Status (21)

Country Link
EP (1) EP1212305A2 (de)
JP (1) JP2002544200A (de)
KR (1) KR20020012567A (de)
CN (1) CN1161345C (de)
AR (1) AR022044A1 (de)
AU (1) AU4754800A (de)
BR (1) BR0010338A (de)
CA (1) CA2370801A1 (de)
CO (1) CO5170461A1 (de)
CZ (1) CZ20013988A3 (de)
HK (1) HK1046138A1 (de)
HU (1) HUP0201181A3 (de)
IL (1) IL146124A0 (de)
MX (1) MXPA01011267A (de)
MY (1) MY138319A (de)
NO (1) NO20015397D0 (de)
NZ (1) NZ515048A (de)
PE (1) PE20010110A1 (de)
PL (1) PL351546A1 (de)
TR (1) TR200103169T2 (de)
WO (1) WO2000068209A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035793A2 (en) * 2003-10-09 2005-04-21 Decode Genetics Ehf. Cckar markers and haplotypes associated with extreme weight conditions
JP4069159B2 (ja) 2004-05-25 2008-04-02 ファイザー・プロダクツ・インク テトラアザベンゾ［ｅ］アズレン誘導体及びそれらのアナログ
BR112022006546A2 (pt) 2019-10-07 2022-08-30 Kallyope Inc Agonistas de gpr119

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9307833D0 (en) * 1993-04-15 1993-06-02 Glaxo Inc Modulators of cholecystokinin and gastrin

Also Published As

Publication number Publication date
JP2002544200A (ja) 2002-12-24
CN1161345C (zh) 2004-08-11
KR20020012567A (ko) 2002-02-16
WO2000068209A3 (en) 2001-03-01
TR200103169T2 (tr) 2002-04-22
PE20010110A1 (es) 2001-03-05
BR0010338A (pt) 2002-02-13
IL146124A0 (en) 2002-07-25
EP1212305A2 (de) 2002-06-12
NO20015397L (no) 2001-11-05
HUP0201181A2 (hu) 2002-12-28
AR022044A1 (es) 2002-09-04
CN1362949A (zh) 2002-08-07
HUP0201181A3 (en) 2003-10-28
PL351546A1 (en) 2003-05-05
NO20015397D0 (no) 2001-11-05
MXPA01011267A (es) 2002-05-06
MY138319A (en) 2009-05-29
AU4754800A (en) 2000-11-21
NZ515048A (en) 2004-01-30
HK1046138A1 (zh) 2002-12-27
CO5170461A1 (es) 2002-06-27
WO2000068209A2 (en) 2000-11-16
CA2370801A1 (en) 2000-11-16

Similar Documents

Publication Publication Date Title
US5646140A (en) 1,5-benzodiazepine derivatives having CCK antagonistic or agonistic activity
US4820834A (en) Benzodiazepine analogs
US5795887A (en) Method of inducing cholecystokinin agonist activity using 1,4- Benzodiazepine compounds
US5519019A (en) N-acyl-2,3-benzoidazepine derivatives, pharmaceutical compositions containing them and process for preparing same
US5639751A (en) N-acyl-2,3-benzodiazepine derivatives for treating acute and chronic neurodegenerative disorders
RU2135485C1 (ru) Производные 1,5-бензодиазепина и содержащий их фармацевтический состав
FR2716195A1 (fr) Dérivés de 3-acylamino-5-phényl-1,4-benzodiazépin-2-one polysubstitués, leur procédé de préparation et les compositions pharmaceutiques les contenant.
US5218114A (en) Cholecystokinin antagonists
JPH08505120A (ja) ベンゾジアゼピン誘導体
US5521174A (en) N-acyl-2,3-benzodiazepine derivatives and a method of treating spasms of the skeletal musculature therewith
AU742498B2 (en) 1,5-benzodiazepine derivatives
US5686449A (en) 1,5-benzodiazepines useful as gastrinor CCK-antagonists
CZ286764B6 (en) 5-Heterocyclo-1,5-benzodiazepine derivatives, process of their preparation and pharmaceutical preparation containing thereof
US6747022B2 (en) Calcium salts of 1,5-benzodiazepine derivatives, process for producing the salts and drugs containing the same
CZ20013988A3 (cs) Enantiomerem obohacené 1,5-benzodiazepinové deriváty
US5399565A (en) Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof
RU2076100C1 (ru) Производные пиразола или их фармацевтически приемлемые соли
AU688316B2 (en) 1,5 benzodiazepine derivatives having CCK and/or gastrin antagonistic activity
US5486514A (en) Carbamate derivatives
US5641775A (en) 3-phenylureido-1,5-benzodiazepine-diones useful as gastrin or antagonists
US5378838A (en) Benzodiazepine cholecystokinin antagonists
US5910495A (en) Use of 1,5-benzo b!1,4-diazepines to control gastric emptying
ZA200108827B (en) 1,5-Benzodiazepine derivatives as CCK-A receptor agonists.
AU2004201385A1 (en) 1,5-benzodiazepine derivatives